The genital warts market size is expected to grow with the anticipated launch of emerging therapies in 7MM and China during the forecast period. LAS VEGAS, Aug. 30, 2022 /PRNewswire/
/PRNewswire/ Lytix Biopharma, a Norwegian immune-oncology company, today releases its second quarter and first half 2022 results - New encouraging clinical.
/PRNewswire/ The CMD is a live event, open for physical attendance at Hotel Continental in Oslo, Norway, as well as a live webcast. It starts at 14.00 CET,.
/PRNewswire/ Lytix Biopharma is pleased to announce that it will host a Capital Markets Day for investors, analysts and media on Wednesday, June 1, 2022 The.